RhumbLine Advisers
BTAI icon

RhumbLine Advisers’s BioXcel Therapeutics BTAI Stock Holding History

RhumbLine Advisers’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-719
Closed -$14.7K – 4215
2024
Q2 		$14.7K Sell
719
-1,136
-61% -$38K ﹤0.01% 3915
2024
Q1 		$83.7K Buy
1,855
+43
+2% +$2.05K ﹤0.01% 3492
2023
Q4 		$85.5K Buy
1,812
+100
+6% +$5.56K ﹤0.01% 3499
2023
Q3 		$69.3K Sell
1,712
-54
-3% -$5.46K ﹤0.01% 3572
2023
Q2 		$188K Sell
1,766
-327
-16% -$109K ﹤0.01% 3265
2023
Q1 		$625K Buy
2,093
+165
+9% +$70.5K ﹤0.01% 2339
2022
Q4 		$663K Buy
1,928
+31
+2% +$7.5K ﹤0.01% 2338
2022
Q3 		$359K Buy
1,897
+115
+6% +$26.7K ﹤0.01% 2645
2022
Q2 		$376K Buy
1,782
+644
+57% +$135K ﹤0.01% 2633
2022
Q1 		$381K Buy
1,138
+132
+13% +$38.3K ﹤0.01% 2541
2021
Q4 		$327K Buy
1,006
+49
+5% +$21K ﹤0.01% 2679
2021
Q3 		$465K Buy
957
+51
+6% +$22.4K ﹤0.01% 2580
2021
Q2 		$421K Buy
906
+58
+7% +$31.6K ﹤0.01% 2642
2021
Q1 		$586K Sell
848
-104
-11% -$83.7K ﹤0.01% 2412
2020
Q4 		$704K Buy
952
+88
+10% +$68.5K ﹤0.01% 2290
2020
Q3 		$599K Sell
864
-102
-11% -$76.6K ﹤0.01% 2201
2020
Q2 		$820K Buy
+966
New +$630K ﹤0.01% 2126

Other funds holding BTAI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

RhumbLine Advisers's BTAI Position: Q3 2024 in Review

RhumbLine Advisers sold out of BioXcel Therapeutics (BTAI) in Q3 2024, closing a stake of 719 shares — an estimated $14.7K sold.

RhumbLine Advisers first reported a position in BTAI in Q2 2020 and held it in 17 quarters. The position peaked at $820K in Q2 2020. 49 funds tracked by Wall St. Rank hold BTAI as of Q3 2024.

  • RhumbLine Advisers reported no remaining BioXcel Therapeutics position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 719 BioXcel Therapeutics shares in Q3 2024, an estimated $14.7K.
  • RhumbLine Advisers first reported a position in BioXcel Therapeutics in Q2 2020 and held it in 17 quarters.
  • RhumbLine Advisers's BioXcel Therapeutics position peaked at $820K in Q2 2020.
  • 49 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.